Kausik K Ray

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
    Kausik K Ray
    Circulation 105:e74. 2002
  2. ncbi Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre
    K K Ray
    Cardiology Department, Doncaster Royal Infirmary, Doncaster, UK
    Int J Clin Pract 60:383-90. 2006
  3. ncbi Optimal goals for statin use in patients with coronary artery disease
    Kausik K Ray
    Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Cardiol 20:525-9. 2005
  4. ncbi The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes
    Kausik K Ray
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1425-33. 2005
  5. ncbi Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials
    Kausik K Ray
    The Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, USA
    Expert Opin Pharmacother 6:915-27. 2005
  6. ncbi Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation
    Kausik K Ray
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Thromb Thrombolysis 18:89-101. 2004
  7. ncbi Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
  8. ncbi A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype
    K K Ray
    Cardiovascular Research Unit, Clinical Sciences Centre North, Northern General Hospital, Sheffield, UK
    J Thromb Haemost 3:287-91. 2005
  9. ncbi Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Lipidol 15:637-43. 2004
  10. ncbi Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009

Detail Information

Publications35

  1. ncbi Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
    Kausik K Ray
    Circulation 105:e74. 2002
  2. ncbi Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre
    K K Ray
    Cardiology Department, Doncaster Royal Infirmary, Doncaster, UK
    Int J Clin Pract 60:383-90. 2006
    ..66, 95% CI 1-2.75, p = 0.049). Patients with non-ST elevation ACS and minimal myonecrosis are a high-risk group more comparable with NSTEMI and clearly distinguishable from patients with UA...
  3. ncbi Optimal goals for statin use in patients with coronary artery disease
    Kausik K Ray
    Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Cardiol 20:525-9. 2005
    ..Coronary artery disease is the largest cause of premature death in the Western world. Lipid-lowering therapy with statins has revolutionized the management of this condition over the past decade...
  4. ncbi The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes
    Kausik K Ray
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1425-33. 2005
    ..This review focuses on the potential importance of these effects in the management of ACS...
  5. ncbi Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials
    Kausik K Ray
    The Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, USA
    Expert Opin Pharmacother 6:915-27. 2005
    ..This suggests that intensive therapy with atorvastatin is associated with a potent pleiotropic effect. This review aims to summarise the recently concluded and ongoing clinical trials and to stimulate further reading...
  6. ncbi Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation
    Kausik K Ray
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Thromb Thrombolysis 18:89-101. 2004
    ..The purpose of this review is to acquaint the reader with the biological changes that accompany ACS, highlight how these pathways may be modulated for clinical benefit by statins and identify potential novel targets for future therapy...
  7. ncbi Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
    ....
  8. ncbi A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype
    K K Ray
    Cardiovascular Research Unit, Clinical Sciences Centre North, Northern General Hospital, Sheffield, UK
    J Thromb Haemost 3:287-91. 2005
    ....
  9. ncbi Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Lipidol 15:637-43. 2004
    ..The mechanisms behind these results are analysed drawing data from vascular and cell biology...
  10. ncbi Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009
    ....
  11. ncbi Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ....
  12. ncbi Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 27:2310-6. 2006
    ..To assess the efficacy and safety of the achievement of the NCEP goal of LDL-C <1.8 mmol/L in elderly patients with ACS...
  13. ncbi Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
    Sean R Wilson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 161:1147-55.e1. 2011
    ..Recent data have suggested a possible discordant adverse risk relationship in acute coronary syndrome (ACS). Therefore, we investigated the association between adiponectin and cardiovascular events in patients with ACS...
  14. ncbi Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:2326-31. 2006
    ..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients...
  15. ncbi Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22)
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 98:861-5. 2006
    ..In conclusion, in this large study of patients with ACS, we provide evidence that increased endothelial activation after ACS is independently associated with increased long-term risk of death, myocardial infarction, or recurrent ACS...
  16. ncbi C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)
    Nazanin Moghbeli
    Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:635-8. 2005
    ..0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease...
  17. ncbi Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1411-6. 2005
    ..This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy...
  18. ncbi Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 28:806-13. 2007
    ..To investigate the relationship between diabetes and inflammation and the potentially synergistic relationship between hyperglycaemia and inflammation on clinical outcomes in non ST-elevation ACS...
  19. ncbi Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy...
  20. ncbi Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome
    Babak Nazer
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 32:1390-7. 2011
    ..406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers...
  21. ncbi High-density lipoprotein and coronary heart disease: current and future therapies
    Pradeep Natarajan
    Department of Medicine, Cardiovascular Division, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:1283-99. 2010
    ....
  22. ncbi Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
    Kausik K Ray
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 96:54F-60F. 2005
    ..The very early benefits of statin therapy appeared to be correlated with CRP reductions, which may relate to the intensity of the pleiotropic effects of statins...
  23. ncbi Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...
  24. ncbi Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    J Am Coll Cardiol 45:1781-6. 2005
    ..CONCLUSIONS: Among patients with unstable coronary syndromes and predominantly normal or mildly reduced GFR, an elevated BUN is associated with increased mortality, independent of sCr-based estimates of GFR and other biomarkers...
  25. ncbi Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
    An H Bui
    Thrombolysis in Myocardial Infarction TIMI Study Group, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Thromb Thrombolysis 34:222-8. 2012
    ..Higher concentration of PlGF after ACS is associated with long-term risk of recurrent cardiovascular events independent of traditional risk factors. This association is present early after ACS and appears to be stronger at four months...
  26. ncbi Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Kausik K Ray
    Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom
    Am J Cardiol 98:18P-25P. 2006
    ..This article reviews some of the key statin trials in ACS and assesses the evidence for benefits of these drugs independent of their effects on LDL cholesterol...
  27. ncbi Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes
    Kausik K Ray
    Cardiovascular Research Group, Division of Clinical Sciences NGH, University of Sheffield, Northern General Hospital, Sheffield S5 7AU, U K
    Clin Sci (Lond) 103:303-10. 2002
    ..0385). These data indicate that, in the setting of non-ST-elevation ACS, genetic variation at the IL-1 gene locus contributes to the changes in soluble markers of endothelial inflammation...
  28. ncbi Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction
    Ajay J Kirtane
    J Am Coll Cardiol 45:321-3. 2005
  29. ncbi Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial
    Satish Bhadriraju
    McLaren Regional Medical Center/Michigan State University, Flint, Michigan, USA
    Am J Cardiol 97:1573-7. 2006
    ..Glucose levels during ACS may be an important addition to the risk stratification of patients with ACS and a potentially important target for therapy...
  30. ncbi Intensive statin therapy in acute coronary syndromes
    Tze Vun Liew
    Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, CB1 8RN, UK
    Curr Atheroscler Rep 10:158-63. 2008
    ..This paper examines the evidence for statin use in ACS...
  31. ncbi Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
    Michael Miller
    Division of Cardiology, University of Maryland Medical Center, Baltimore, Maryland 21201, USA
    J Am Coll Cardiol 51:724-30. 2008
    ..The purpose of this study was to assess the impact of on-treatment triglycerides (TG) on coronary heart disease (CHD) risk after an acute coronary syndrome (ACS)...
  32. ncbi Biomarkers, C-reactive proteins and statins in acute coronary syndromes
    Kausik K Ray
    Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
    Fundam Clin Pharmacol 21:31-3. 2007
    ..Further understanding the role of different biomarkers will help better understand the pathophysiology of ACS as well as provide personalized medical care...
  33. ncbi Aggressive statin therapy for acute coronary syndromes
    Tze Vun Liew
    Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK
    Curr Cardiol Rep 9:298-302. 2007
    ..This article examines this emerging evidence for the use of statins in ACS...
  34. ncbi Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome
    Kausik K Ray
    Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Circulation 115:3071-8. 2007
    ..Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease...
  35. ncbi Intensive statin therapy for treating acute coronary syndromes
    Kausik K Ray
    University of Cambridge, Department of Public Health and Primary Care, Strangeways Research Laboratory, Addenbrookes Hospital, Cambridge, CB1 8RN, UK
    Expert Opin Investig Drugs 15:1151-9. 2006
    ..This paper reviews the current state of evidence from the key statin trials in ACS and their implications for the future management of ACS...